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Mutations in the pfcrt and pfmdr1 genes have been associated with chloroquine resistance in Plasmodium
falciparum. Ten and five mutations, respectively, have been identified in these genes from chloroquine-resistant
parasites worldwide. Mutation patterns in pfcrt revealed that chloroquine resistance evolved independently in
southeast Asia, South America, and Papua New Guinea. However, the evolution of chloroquine resistance in the
rest of the Pacific region is unclear. In this study, we examined sequence polymorphisms in these genes in
isolates from Morong, Philippines, and compared them to known chloroquine resistance sequences. Two novel
mutations, A144T and L160Y, were identified outside of the 10 known mutations in pfcrt in Morong isolates.
These novel mutations were identified only in parasites with K76T and N326D but without the common A220S
mutation found in most chloroquine-resistant isolates. This represents a unique chloroquine resistance allelic
type (K76T/A144T/L160Y/N326D) not previously found elsewhere in the world. One Morong isolate also had
an additional C72S mutation, whereas only one isolate possessed an allelic type typical of chloroquine
resistance in Asia. Parasites with the novel pfcrt allelic types were resistant to chloroquine in vitro and were
unresponsive to verapamil (0.9 M) chemosensitization, similar to chloroquine-resistant parasites from South
America and Papua New Guinea. These results suggest that chloroquine resistance evolved independently in
the Philippines and represents a second chloroquine resistance founder event in the South Pacific.
Recent studies on the molecular mechanism of chloroquine
resistance in Plasmodium falciparum have led to the identifi-
cation and characterization of the pfcrt gene (9). Genetic mu-
tations in pfcrt were reported to be associated with reduced in
vitro susceptibilities to chloroquine in laboratory lines and field
isolates (1, 5, 9, 12). Mutations in the pfcrt gene has also been
shown, by episomal complementation assay (9) and allelic ex-
change techniques (17), to confer chloroquine resistance in
laboratory strains. These studies suggest that the PfCRT pro-
tein plays a fundamental role in chloroquine resistance.
In previous studies, point mutations were observed in 10
codons in the pfcrt gene of chloroquine-resistant parasite iso-
lates from various regions. These include mutations at amino
acid positions 72, 74, 75, 76, 97, 220, 271, 326, 356, and 371. In
general, the chloroquine-resistant parasite isolates from South-
east Asia and Africa have pfcrt genes with seven to nine mu-
tated codons, and their mutated codons are linked into a pat-
tern of CIETH(L)SEST(I)I, from positions 72 to 371 (9, 21).
The chloroquine-resistant parasites from South America and
Papua New Guinea possess pfcrt genes with four to five mu-
tated codons forming patterns of S(C)MNTHSQDLR (5, 9,
21).
The minimum number of mutations previously reported in
pfcrt of chloroquine-resistant parasites was four: C72S, K76T,
N326D, and I356L (21). The mutation K76T was found in all
chloroquine-resistant parasites and A220S was found in all but
two chloroquine-resistant isolates so far sequenced (5, 9, 11,
21), indicating their essential role in chloroquine resistance.
The role of the remaining pfcrt mutations in chloroquine re-
sistance remains unclear. The number and pattern of the four
to nine mutations in the pfcrt gene were not associated with the
levels of chloroquine resistance (5); however, the pfcrt allelic
type of the chloroquine-resistant parasites has been shown to
be linked with the chloroquine-resistant parasite’s response to
verapamil chemosensitization (12). Chloroquine-resistant par-
asites with South American or Papua New Guinea allele of
pfcrt are less responsive to verapamil than those with the
Southeast Asian allele (12).
Based on the diversity of pfcrt allelic types and flanking
microsatellite markers, it has been proposed that chloroquine-
resistant parasites originated from at least four independent
foci: (i) in Asia spreading to Africa, (ii) in Papua New Guinea,
and (iii) two sites in South America (Peru and Colombia) (21).
The finding that pfcrt allelic types in Papua New Guinea (5, 12)
were different from those found in Asia was a surprise, as
previously chloroquine resistance was thought to have mi-
grated south and east from Asia into Oceania (18). Chloro-
* Corresponding author. Mailing address: Department of Drug Re-
sistance and Diagnostics, Australian Army Malaria Institute, Weary
Dunlop Drive, Gallipoli Barracks, Enoggera, Qld 4051, Australia.
Phone: 61-7-3332 4834. Fax: 61-7-3332 4800. E-mail: qin.cheng
@defence.gov.au.
† Present address: Infectious Diseases Unit, Queensland Institute of












quine resistance has been widely reported in the Philippines
(2) and other South Pacific island countries (14); however, in
light of the new data, the evolution and spread of chloroquine
resistance within the region are not clear.
In this study, we examined the pfcrt gene in 20 P. falciparum
isolates collected from Morong, Philippines. Most of these
possessed only two of the 10 previously known mutations
(K76T and N326D) in pfcrt, yet they also had two novel mu-
tations, A144T and L160Y, not observed previously. The sus-
ceptibilities of parasites with the unique allelic types to chlo-
roquine and desethyl chloroquine were investigated, as were
their responses to verapamil chemosensitization.
MATERIALS AND METHODS
P. falciparum isolates and lines. P. falciparum isolates PH1 to PH10, PH12,
and PH16 were collected from Morong, Bataan, Luzon, Philippines, in 1989 to
1991 as part of a baseline malaria epidemiological survey. PH21 to PH28 were
collected in the same area 1 to 2 years later (1992 to 1993) in cross-sectional
surveys (13). A detailed description of the area has been published (3). FCQ27-
D10, K1, and 7G8 are laboratory lines originally from Papua New Guinea,
Thailand, and Brazil, respectively. P. falciparum isolates collected from Papua
New Guinea (6), Solomon Islands (15), and Bougainville and Thailand (5) were
described previously.
PCR amplification of the P. falciparum genes. Genomic DNA was extracted
from the cultured parasites with methods described previously (7). P. falciparum
gene fragments to be studied were amplified by PCR in 50-l reaction mixture
containing 1.5 g/ml of each primer, 200 M deoxynucleoside triphosphates,
buffer (50 mM KCl, 10 mM Tris-HCl, pH 8.3), 2.5 mM MgCl2, and 1.25 units of
AmpliTaq Gold DNA polymerase (PE Applied Sciences). msp1, msp2, and glurp
were amplified and their fragment sizes were analyzed by agarose gel electro-
phoresis (16). Three pfcrt fragments were amplified with the following cycle
conditions: 94°C 10 min, then 94°C for 50 s, 51°C for 50 s, and 70°C for 1 min for
40 cycles: (i) a fragment flanking codons 72, 74, 75, 76, and 97 with primers D1
(5-TGT GCT CAT GTG TTT AAA CTT-3) (8) and D3 (5-AAA GCT TCG
GTG TCG TTC-3); (ii) a fragment flanking codon 220 with primers E3 (5-CTT
ATA CAA TTA TCT CGG AGC AGT-3) and F1 (5-GTC ATG TTT GAA
AAG CAT ACA GG-3); and (iii) a fragment flanking codon 271 with primers
E4 (5-CCA AGA ATA AAC ATG CGA AAC C-3) and F2 (5-ATT TCT TAT
AGG CTA TGG TAT CC-3).
A fourth fragment of pfcrt flanking codons 326, 356, and 371 was amplified by
nested PCR with primers D7 (5-TTT CTA AGA TAA TAT TTC CTA CAC-3)
and F3 (5-TAG AAA ACC TTC GCA TTG-3) (94°C for 10 min, then 94°C for
50 s, 45°C for 50 s, and 70°C for 1 min for 40 cycles), and then F3 and F4 (5-ACT
TAC CAA AGT TAC GAA ATC-3) (94°C for 10 min, then 94°C for 50 s, 50°C
for 50 s, and 70°C for 1 min for 30 cycles). A fifth fragment flanking codons 144
and 160 was amplified with primers 4A (5-TAGGAACGACACCGAAG-3)
and 4B (5-ATAGTATACTTACCTATATC-3) (94°C for 10 min, then 94°C for
50 s, 45°C for 50 s, and 70°C for 1 min for 45 cycles).
Isolation of total RNA and RT-PCR to amplify a 1,013-bp fragment of the
coding sequence of pfcrt (codons 44 to 380). Total RNA was extracted from the
cultured parasites (PH1, PH3, PH4, PH5, PH7, PH9, PH10, and FCQ27-D10)
with a NucleoSpin RNAII System (Macherey-Nagel GmbH & Co., Germany).
cDNA was amplified by reverse transcription (RT)-PCR with a SuperScript
One-Step RT-PCR System (Invitrogen Life Technologies) and primers D1 and
F4 with the following conditions: 42°C for 30 min, 94°C for 2 min, then 94°C for
50 s, 50°C for 50 s, and 70°C for 1 min for 40 cycles. Fragments of pfmdr1-flanking
mutations were also amplified and analyzed (4).
Purification and sequencing of the pfcrt PCR fragments. The PCR products
were purified with a NucleoSpin Extract System (Macherey-Nagel GmbH & Co.,
Germany) following agarose gel electrophoresis, and then sequenced in an ABI
Prism 370 sequencer.
In vitro chloroquine susceptibility tests. Parasites were maintained in vitro
with conditions modified from those described by Trager and Jensen (19). In
vitro susceptibilities to chloroquine and desethyl chloroquine were tested, and
50% inhibitory concentration (IC50) and IC90 values were determined as de-
scribed previously (12). Verapamil (0.9 M) was included in one set of suscep-
tibility tests to determine the effect of verapamil on the chloroquine resistance
phenotypes of the parasite samples (12).
Nucleotide sequence accession number. The cDNA sequence of PH1 repre-
senting the major novel pfcrt allelic type has been deposited in the GenBank
database with accession number AY254700.
RESULTS
Novel pfcrt allelic types. Twenty P. falciparum isolates col-
lected from the Morong area of the Philippines were examined
in this study. Genotyping of three polymorphic markers, msp1,
msp2, and glurp, indicated that 18 out of the 20 isolates were of
a single clone of parasite; the remaining 2 isolates (PH6 and
PH10) had more than one clone of parasite (data not shown).
Sequence polymorphisms in pfcrt, in particular the 10 codons
reported to be associated with chloroquine resistance (9), were
examined for these isolates, and the results are shown in Table
1.
Compared to the wild-type chloroquine-sensitive PFCRT
sequence CMNKHAQNIR in FCQ27-D10, the pfcrt gene of 18
Morong isolates (PH1, PH3, PH5 to PH10, PH12, PH16, and
PH21 to PH28) possessed only two mutated codons, K76T and
N326D, giving allelic type CMNTHAQDIR (Table 1). One
isolate (PH2) had three mutated codons: C72S, K76T and
N326D giving an allelic type of SMNTHAQDIR (Table 1).
The remaining isolate (PH4) was of the Southeast Asian allelic
type (CIETHSESTI) and had eight mutations. These three
allelic types are named P2a, P2b, and E1a, respectively (Table
1) according to the nomenclature used by Wellems and Plowe
(20). The P allelic type, originally proposed for Papua New
Guinea, was extended to include other Pacific region countries
where similar allelic types evolved. All 20 Morong isolates were
found to carry the K76T mutation, which has been identified as
crucial for chloroquine resistance. Interestingly, A220S, a mu-
tation that is almost always linked with the K76T mutation in
chloroquine-resistant parasites elsewhere, was present in only
one parasite with the Asian allelic type (PH4), but not in the
remaining 19 Morong isolates.
Previously it was suggested that a minimum of four muta-
tions were required to confer chloroquine resistance (21). The
surprising finding that most of the Morong isolates had muta-
tions in only two of the ten known positions led us to investi-
gate the cDNA sequence for seven of these isolates. Two novel
mutations, A144T and L160Y, were detected in each of the
isolates that also had K76T and N326D (Table 1). To investi-
gate the frequency of these two novel mutations, primers 4A
and 4B were used to amplify the gene fragment containing
these positions in the remaining Morong isolates. In total,
A144T and L160Y were identified in 19 of the 20 Morong
isolates examined, including 11 isolates collected from the pilot
study (1989 to 1991) and 8 from two separate surveys (1992 to
1993); the only exception was PH4, which was the only isolate
found with an Asian allelic type for pfcrt (Table 1).
The presence of these unique mutations in pfcrt in isolates
from Morong led us to investigate their possible occurrence in
chloroquine-resistant parasites from other Pacific island coun-
tries. In contrast to Morong parasites, no mutations were
found at position 144 or 160 in isolates collected from Papua
New Guinea (chloroquine sensitive: n  5, chloroquine resis-
tant: n  7), Solomon Islands (n  4), and Thailand (n  5)
(Table 1). A further examination of these two positions in
Bougainville (n  25), Solomon Islands (n  8), East Timor (n











 23), Thailand (n  9), Cambodia (n  3), and Vietnam (n
 10) P. falciparum isolates failed to detect these mutations
(data not shown). These data suggest that the two novel
pfcrt allelic types, CMNTHTYAQDIR (type P2a) and
SMNTHTYAQDIR (type P2b), may be present only in the
Philippines.
pfmdr1 types. Sequence polymorphism in pfmdr1 was exam-
ined for the Morong isolates. The amino acids encoded at
positions 86, 184, 1034, 1042, and 1246 were Y, Y, S, N, and D,
respectively, for all isolates except PH4. PH4, the only isolate
with the Southeast Asian pfcrt allelic type, also had a different
pfmdr1 allelic type than the rest of the isolates (Table 1).
Isolates with novel pfcrt allelic types were resistant to chlo-
roquine. Five Morong isolates with one of the novel allelic
types (type P2a), K76T/N326D/A144T/L160Y (PH1, PH3,
PH5, PH9, and PH10), and one isolate with the Southeast
Asian allelic type (PH4, type E1a) were tested for their sus-
ceptibility to chloroquine and desethyl chloroquine, the pri-
mary human metabolite of chloroquine. Standard laboratory
parasite lines FCQ27-D10 (chloroquine sensitive), K1 (chloro-
quine resistant, type E1b) and 7G8 (chloroquine resistant,
typeW1a) were included as controls. Unfortunately, the other
novel allelic type (type P2b), represented by PH2, could not be
tested because it failed in adaptation to in vitro cultivation.
Parasites with the novel Morong allelic type (P2a) pfcrt
showed a significant increase in chloroquine IC50 (2.76- to
8.33-fold) and IC90 (4.41- to 9.8-fold increase) compared to a
known chloroquine-sensitive parasite, FCQ27-D10. This de-
creased susceptibility to chloroquine was comparable to that of
7G8 but lower than that observed for K1 (Table 2). Similar
trends were observed for desethyl chloroquine (Table 2). PH4
parasites (type E1a) (CIETHSESTI) showed IC50 and IC90
values for chloroquine and desethyl chloroquine comparable
to those of the other five Morong isolates tested (Table 2).
Isolates with novel pfcrt allelic type were not responsive to
0.9 M verapamil. Verapamil (0.9 M) was used to assess the
degree of potentiation observed in the presence of chloroquine
and desethyl chloroquine. Similar to the chloroquine-resistant
Brazilian strain 7G8, the Morong isolates with the novel pfcrt
genotypes were not responsive to verapamil chemosensitiza-
tion (Table 2). The resistance modification indices (RMI; IC50
or IC90 in the presence of verapamil/IC50 or IC90 in the ab-
sence of verapamil) for the Morong isolates indicated little to
no effect of verapamil on the response to chloroquine at either
the IC50 or IC90 level. These results were similar to the results
obtained for 7G8. In contrast, the RMI for PH4 was 0.37,
which was comparable to that of K1 (0.36), indicating a rever-
sal of chloroquine resistance in the presence of verapamil
(Table 2). Similarly, verapamil had no effect on the response to
desethyl chloroquine in the 7G8 or Morong parasites with the
novel allelic types (Table 2). In contrast, resistance to desethyl
chloroquine was reversed by verapamil in parasites with an
Asian pfcrt allelic type (PH4 and K1).






Amino acid in PfCRT at position: Amino acid in PfMDR1 atposition:
72 74 75 76 97 144 160 220 271 326 356 371 86 184 1034 1042 1246
Papua New Guinea Wild FCQ272,5/30/46/50/643 C M N K H A L A Q N I R N Y S N D
Thailand Ela CH125/AA071/AA0722 C I E T H A L S E S T I N Y S N D
Elb K12 C I E T H A L S E S I I Y Y S N D
Elc TM93-C10882 C I E T L A L S E S T I N F C D Y
PNG Pla AN001/018/070/077/1432 S M N T H A L S Q D L R Y Y S N D
Pla FCQ23 S M N T H A L S Q D L R Y Y S N D
Pla FCQ223 S M N T H A L S Q D L R N Y S N D
Plb PNG42 S M N T H A Q D L R
Philippines P2a PH1 (18 isolates)3,4,5 C M N T H T Y A Q D I R Y Y S N D
P2b PH23 S M N T H T Y A Q D I R Y Y S N D
Ela PH43,5 C I E T H A L S E S T I N F C D D
Solomon Pla N18/N70/S55/S993 S M N T H A L S Q D L R Y Y S N D
Brazil W1a 7G82 S M N T H A L S Q D L R N F C D Y
Ecuador W1b Ecu 11102 C M N T H S Q D L R
Colombia W2a Jav2 C M E T Q S Q N I T
Cambodia NA 462 C M N T A
NA 1082 C I D T S
a Types E, W, and P refer to resistance foci originating in the eastern and western hemispheres and in the Pacific respectively (20). NA, not available due to
incomplete sequence. Shaded, mutated amino acids; bold, positions where mutations were observed in P2 allelic types in Morong isolates. 2The data for FCQ27, CH125,
AA071, AA072, K1, TM93-C1088, AN001, AN018, AN070, AN077, AN143, PNG4, 7G8, Ecu1110, Jav, Cambodia 46 and 108, except for codons 144 and 160, have
been published (5, 9, 11, 21) and are used to compare with the Philippines samples in the present study. 3New pfcrt sequence data reported in this paper. 4This pfcrt
allelic type was identified in 18 isolates: PH1, 3, 5 to 10, 12, 16, and 21 to 28. 5cDNA sequence of pfcrt was analyzed for the following samples: FCQ27-D10, PH1, PH3,
PH4, PH5, PH7, PH9, and PH10.











Responses to quinine and mefloquine. All Morong isolates
tested were susceptible to mefloquine; however, the response
to quinine differed between the isolates (Table 3). PH4, similar
to K1, showed elevated IC50 (57.63  20.01 ng/ml) and IC90
(233.62  75.72 ng/ml) to quinine. The remaining Philippine
isolates showed significantly lower IC50 and IC90 for quinine
compared to PH4. Interestingly, the quinine response of the
only Morong isolate with an Asian pfcrt allelic type (PH4) was
not affected by verapamil, whereas K1 resistance to quinine
was reduced by 55 to 62% in the presence of verapamil, as
previously reported for Asian chloroquine-resistant isolates
(10). Verapamil had no effect on the response to mefloquine in
any of the parasites tested (Table 3).
DISCUSSION
In the current study, we identified two novel allelic types of
the pfcrt gene in chloroquine-resistant P. falciparum isolates
collected from Morong, Philippines. These pfcrt allelic types
include two novel mutations (A144T and L160Y) in combina-
tion with two or three mutated codons (K76T/N326D or C72S/
K76T/N326D) from within the previously reported repertoire
of 10 codons. Parasites possessing the allelic type K76T/
N326D/A144T/L160Y were resistant to chloroquine and des-
ethyl chloroquine in vitro but were susceptible to quinine and
mefloquine.
These two novel allelic types found in Morong, Philippines,
represent the first indication that mutated codons in pfcrt exist
outside the 10 positions found in chloroquine-resistant isolates
from Asia, Africa, Papua New Guinea, and South America.
The same allelic type was observed in 19 of 20 isolates exam-
ined that were collected over a 4-year period, suggesting that
these alleles were stably maintained in the area. From our
examination of pfcrt sequences in a limited number of isolates
from Papua New Guinea, Solomon Islands, East Timor, Indo-
nesia, Vietnam, and Thailand, the A144T and L160Y muta-
tions were identified only in the Philippines. Whether these
pfcrt allelic types are unique to the Morong area or common to
other islands in the Philippines requires further investigation.
Clearly, the occurrence of these novel pfcrt genotypes suggests
that chloroquine-resistant parasites evolved independently in
the Philippines rather than being spread from Southeast Asia,
the Americas, or Papua New Guinea. Therefore, the K76T/
N326D/A144T/L160Y allele likely represents the fifth founder
event for the evolution of chloroquine resistance, with the
other four foci being in Southeast Asia, Papua New Guinea,
Colombia, and Peru (21).
One of the 20 Morong isolates studied was of a pfcrt allelic
type identical to the Southeast Asia type (type E1a), which
suggests that chloroquine resistance is also spreading from
Southeast Asia. The difference in its pfmdr1 allelic type com-
pared to the rest of the isolates provides further support that
this parasite was introduced into the region from Southeast
Asia. The Morong area is effectively isolated on three sides,
and contact with other areas occurs only along a narrow coastal
strip to the south. It is an area of very low malaria endemicity;
however, at the time these isolates were collected, there was a
refugee processing center in the area, funded by the United
Nations High Commission for Refugees, that housed 11,000 to
16,000 refugees from Southeast Asia (3). It is highly probable
that parasites carried by these Asian refugees have spread to
local communities.






IC50 (SD) RMI IC90 (SD) RMI IC50 (SD) RMI IC90 (SD) RMI
7G8  34.32 (4.05) 0.97 73.03 (8.77) 0.91 276.15 (25.62) 0.94 610.41 (131.5) 0.78
 33.24 (12.72) 66.76 (12.0) 259.34 (43.93) 474.49 (80.0)
D10  6.04 (0.83) 1.04 10.27 (1.18) 1.39 13.94 (1.60) 1.27 18.98 (2.31) 1.27
 6.26 (1.73) 14.28 (3.62) 17.74 (2.79) 24.06 (1.91)
K1  75.22 (1.72) 0.36 110.71 (16.48) 0.49 544.98 (182.5) 0.37 781.64 (155.2) 0.45
 27.10 (10.12) 54.54 (19.45) 200.51 (86.7) 349.99 (161.6)
PH1  30.43 (8.77) 0.77 63.68 (17.76) 0.95 211.49 (25.36) 0.79 446.93 (70.84) 0.88
 23.51 (5.82) 60.52 (14.88) 166.31 (3.10) 395.44 (50.12)
PH3  50.29 (5.72) 0.94 101.64 (2.02) 1.03 345.19 (45.83) 0.88 645.82 (93.8) 0.98
 47.33 (2.74) 105.18 (8.07) 305.35 (14.23) 631.39 (127.3)
PH4  47.21 (11.82) 0.37 105.26 (7.85) 0.37 306.37 (116.3) 0.48 732.87 (28.90) 0.38
 17.25 (3.47) 38.80 (15.80) 146.11 (13.63) 280.91 (94.28)
PH5  16.68 (6.79) 0.65 45.25 (19.70) 1.05 141.20 (44.28) 0.74 313.68 (146.65) 0.86
 10.81 (4.09) 47.35 (20.79) 104.19 (42.87) 269.46 (84.49)
PH9  45.98 (3.31) 1.06 37.24 (4.75) 1.55 327.06 (76.83) 0.92 589.90 (60.89) 0.95
 48.72 (2.87) 57.69 (8.63) 301.04 (20.07) 561.66 (88.03)
PH10  41.82 (11.85) 1.34 88.07 (47.35) 1.05 284.53 (23.93) 1.28 539.02 (834.04) 1.19
 56.08 (18.99) 92.39 (5.34) 364.04 (116.93) 643.57 (120.64)
a IC50 and IC90 values are in nanograms per milliliter.











The tandem occurrence of K76T and A220S, located in
predicted transmembrane domains (TMDs) 1 and 6, respec-
tively, in almost all previously examined chloroquine-resistant
isolates has suggested that these mutations play an essential
role in conferring chloroquine resistance (9, 21). Interestingly,
all Morong isolates with novel pfcrt allelic types have the K76T
mutation but not the A220S mutation. Instead, these isolates
have mutations of A144T and L160Y, which are located in
predicted TMDs 3 and 4. Although the relative importance of
the A144T and L160Y mutations in conferring chloroquine
resistance is not clear, thus far we have not found these mu-
tations coexisting with A220S in any other isolate. Besides the
Morong isolates, only two chloroquine-resistant isolates have
been reported that have K76T not accompanied by A220S (11,
21). However, the full-length sequence of the gene was not
determined in either report, and it is unknown whether addi-
tional mutations exist in these isolates.
Therefore, the alternative presence of these two new muta-
tions and their predicted locations in TMDs led us to hypoth-
esize that A144T and L160Y may be compensatory mutations
that can confer chloroquine resistance in the absence of
A220S. If this hypothesis is correct, the K76T mutation plus
one mutation in predicted TMD 6 or two mutations in TMDs
3 and 4 are required to confer chloroquine resistance. How-
ever, one possibility that we cannot rule out is that the A144T
and L160Y mutations may occur in chloroquine-sensitive par-
asites in Morong and were inherited by chloroquine-resistant
parasites. The full-length sequences of pfcrt genes from chlo-
roquine-sensitive parasites in Morong or allelic replacement
studies are required to confirm the role of the new pfcrt mu-
tations (A144T and L160Y) in chloroquine resistance.
Interestingly, the novel Morong pfcrt allelic types P2a and
P2b (CMNTHTYAQDIR and SMNTHTYAQDIR) are more
closely related to the SMNTHSQDLR types reported for chlo-
roquine-resistant parasites from South America and Papua
New Guinea than to the CIETHSESTI type in Southeast Asia
and Africa. Similar to parasites with the South American and
Papua New Guinea allelic types (12), the chloroquine suscep-
tibility of Morong parasites with the novel pfcrt allele was not
affected by verapamil (0.9 M). These data are consistent with
the possibility that amino acids at positions 74 to 76 and/or 271,
326, and 371 are linked with the parasite response to verapamil
and that the 74I/75E/76T and/or 271E/326S/371I mutations in
pfcrt are positively associated with verapamil reversibility of
chloroquine resistance.
The prevalence of two novel pfcrt allelic types in Morong,
Philippines, suggests that chloroquine resistance evolved inde-
pendently in the Philippines and represents the fifth founder
event for chloroquine resistance worldwide. The fact that two
founder events have occurred in South Pacific island countries
may be due to their geographic isolation, especially in the
1960s, when chloroquine resistance first emerged in the region.
Additional studies are required to determine the unique diver-
sity of pfcrt alleles in the South Pacific to determine if chloro-
quine resistance emerged independently in additional loci.
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IC50 (SD) RMI IC90 (SD) RMI IC50 (SD) RMI IC90 (SD) RMI
7G8  33.14 (8.36) 1.22 147.00 (50.73) 0.91 1.56 (0.68) 1.42 5.11 (2.72) 1.02
 40.55 (1.76) 133.06 (1.90) 2.21 (0.08) 5.23 (0.32)
D10  17.48 (8.09) 1.46 67.28 (12.27) 1.37 18.84 (9.43) 1.41 38.96 (21.08) 1.39
 25.47 (11.18) 91.93 (43.48) 26.55 (2.60) 54.12 (4.00)
K1  54.30 (19.10) 0.45 254.87 (96.94) 0.38 4.70 (2.62) 0.95 9.76 (3.92) 0.93
 24.63 (6.57) 96.94 (43.37) 4.46 (0.39) 9.04 (1.34)
PH1  5.86 (5.43) 1.21 33.45 (34.9) 1.16 3.20 (0.06) 0.82 7.55 (1.12) 0.86
 7.11 (6.45) 38.84 (36.39) 2.61 (0.09) 6.46 (0.27)
PH3  11.33 (1.19) 1.47 50.07 (26.24) 1.12 4.09 (0.13) 0.87 8.11 (0.66) 0.95
 16.71 (6.26) 56.30 (27.62) 3.57 (0.22) 7.74 (0.42)
PH4  57.63 (20.01) 1.00 233.62 (75.72) 0.84 1.41 (0.88) 1.12 4.84 (2.52) 1.31
 57.83 (26.95) 197.04 (76.55) 1.58 (0.37) 6.36 (1.03)
PH5  15.56 (13.80) 1.52 110.54 (129.37) 1.22 1.48 (0.75) 1.13 4.44 (3.79) 1.27
 23.72 (20.5) 134.40 (103.61) 1.67 (0.76) 5.62 (2.85)
PH9  12.16 (1.28) 1.27 37.24 (11.41) 1.55 3.53 (0.12) 0.93 7.44 (0.79) 0.92
 15.41 (4.61) 57.69 (16.73) 3.28 (0.18) 6.82 (.033)
PH10  11.33 (1.19) 1.47 50.07 (26.24) 1.12 4.09 (0.13) 0.87 8.11 (0.66) 0.95
 16.71 (6.26) 56.30 (27.62) 3.57 (0.22) 7.74 (0.42)
a See Table 2, footnote a.
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